Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 313-320

  Rakieh, Chadi ^a   Conaghan, Philip G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Abatacept; Rheumatoid arthritis; T cell; Therapy

Indexed keywords

ABATACEPT; ADALIMUMAB; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

AUTOIMMUNE DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HUMAN; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; JOINT RADIOGRAPHY; LOADING DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 84899808818     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S60740     Document Type: Review

References (33)

1. Munro R, Hampson R, McEntegart A, Thomson EA, Madhok R, Capell H. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a fve year prospective study. Ann Rheum Dis. 1998;57(2):88-93.
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-3390.
3. van der Heide A, Jacobs J W, Bijlsma JW, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 1996;124(8):699-707.
4. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Beneft of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatolog y (Oxford). 2004;43(7):906-914.
5. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509.
6. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3): 516-528.
7. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med. 1998;338(25): 1813-1821.
8. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol. 1996;14: 591-617.
9. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T-cell costimulation. Annu Rev Immunol. 1996;14:233-258.
10. Quattrocchi E, Dallman MJ, Feldmann M. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum. 2000;43(8):1688-1697.
11. Larsen C P, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381(6581):434-438.
12. Corbo M, Valencia X, Raymond R, Summerill R, Agrawal S, Townsend R. Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity. Ann Rheum Dis. 2009;68:S574.
13. Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and Efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68(11):1708-1714.
14. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-1123.
15. Westhovens R, Kremer JM, Moreland LW, et al. Safety and Efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended Phase IIB study. J Rheumatol. 2009;36(4):736-742.
16. Kremer JM, Russell AS, Emery P, et al. Long-term safety, Efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70(10):1826-1830.
17. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865-876.
18. Westhovens R, Robles M, Ximenes AC, et al. Clinical Efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12): 1870-1877.
19. Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a Phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011;63(10):2854-2864.
20. Nash P, Nayiager S, Genovese MC, et al. Immunogenicity, safety, and Efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a Phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken). 2013;65(5):718-728.
21. Kaine J, Gladstein G, Strusberg I, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, Efficacy and safety (Phase Iiib ALLOW study). Ann Rheum Dis. 2012;71(1):38-44.
22. Keystone EC, Kremer JM, Russell A, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the Phase IIIb ATTUNE study. Ann Rheum Dis. 2012;71(6):857-861.
23. Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: fndings of a Phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28-38.
24. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year Efficacy and safety fndings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86-94.
25. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27(1):261-263.
26. Genovese M, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M. Subcutaneous abatacept: long-term data from the ACQUIRE trial. Arthritis Rheum. 2012;64(Suppl 10):S201.
27. Schellekens H. Factors infuencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20 Suppl 6:vi3-vi9.
28. Haggerty HG, Abbott MA, Reilly T P, et al. Evaluation of immunogenicity of the T-cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol. 2007;34(12):2365-2373.
29. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and Efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(1): 40-46.
30. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921-926.
31. Alten R, Kaine J, Keystone E, et al. Safety profle of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposure. Arthritis Rheum. 2011;63:S150.
32. Alten R, Kaine J, Keystone E, Nash P, Delaet I, Qi K. Safety of subcutaneous abatacept in patients with rheumatoid arthritis (RA): integrated analysis of fve clinical trials up to 4.5 years. Ann Rheum Dis. 2011; 70 Suppl 3:617.
33. Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatolog y (Oxford). 2006;45(12):1575-1576.